Gilead Sciences, Inc.

Cv Therapeutics, Inc.

Gilead Palo Alto, Inc.

Dmitry Koltun

Jeff A Zablocki

Eric Q Parkhill

Elfatih O Elzein

Rao V Kalla

Thao Perry

Xiaofen Li

Robert H Jiang

Britton Kenneth Corkey

Chandrasekar Venkataramani

Michael Graupe

Juan A Guerrero

Ruben Martinez

Gregory Notte

Tetsuya Kobayashi

Timur Mikhailovich Zilbershtein

Natalya Vasilevich

Scott Preston Simonovich

Alexey Ivanov

Andrey Glushkov

Jeffrey Chisholm

Richard L Mackman

Dustin S Siegel

Byoung-Kwon Chun

Petr Jansa

Mark J Bartlett

Michael O Clarke

Daniel H Byun

Matthew Abelman

Jennifer Leigh Cosman

Kristyna M Elbel

Melanie Boze

Prabha N Ibrahim

Lianhong Xu

Kevin D Shenk

Ryan McFadden

Michael R Mish

David Sperandio

Hai Yang

Gregory F Chin

Yunfeng Eric Hu

Michael G Campbell

Xiaochun Han

Ian Henderson

Andrew Graham Cole

Christopher F Morrison

Christopher Allen Ziebenhaus

Michael O' Neil Hanrahan Clarke

Reina Natero

William Shirley

Tsung Lin

Andrei Glushkov

Tim Hansen

Eifatih Elzein

Jeff Zablocki

Britton Corkey

Robert Jiang

Eric Parkhill

Rao Kalla

Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

1'-cyano nucleoside analogs and uses thereof

1′-cyano nucleoside analogs and uses thereof

Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: 

Therapeutic heterocyclic compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

Imidazopyrimidine derivatives

The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R, R, R, R, R, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as CaM kinase inhibitors

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W, W, W, R, Q, X, Xand Xare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R, R, R, R, and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Growing community of inventors

Foster City, CA, United States of America

Dmitry Koltun